Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration

Published: Sept 10, 2021 | Tags: Boehringer Ingelheim, Twist, Therapeutic Antibodies, Multiple Targets

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD

Published: Sept 10, 2021 | Tags: Samsung Bioepis, Post-Hoc Analysis, P-III, Study, Byooviz, biosimilar, ranibizumab, nAMD

Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) Receive the US FDA’s Breakthrough Therapy Designation for the Treatment of Heart Failure with Preserved Ejection Fraction

Published: Sept 10, 2021 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, Breakthrough Therapy Designation, Heart Failure, Preserved Ejection Fraction, US

Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

Published: Sept 10, 2021 | Tags: Dermavant, P-III, ADORING Program, Tapinarof, Atopic Dermatitis

Roche to Acquire TIB Molbiol for Bolstering its Molecular Diagnostics Portfolio

Published: Sept 10, 2021 | Tags: Roche, TIB Molbiol, PCR-Test Portfolio, Infectious Diseases

Eli Lilly Signs a License and Research Agreement with ProQR to Develop & Commercialize RNA Therapeutic for the Treatment of Liver and Nervous System Disorders

Published: Sept 10, 2021 | Tags: Eli Lilly, ProQR, RNA Therapeutic, Liver, Nervous System

ICU Medical Commits to Acquire Smith for ~$2.35B

Published: Sept 9, 2021 | Tags:  ICU Medical, Acquire, Smith, ~$2.35B

Cardiff Oncology Reports Results of Onvansertib in P-Ib/II Trial for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer

Published: Sept 9, 2021 | Tags: Cardiff Oncology, Onvansertib, , KRAS-Mutated Metastatic Colorectal Cancer

AstraZeneca Reports Results of PT027 (albuterol and budesonide) in P-III MANDALA and DENALI Trials for the Treatment of Asthma

Published: Sept 9, 2021 | Tags: AstraZeneca, PT027, albuterol, budesonide, P-III, MANDALA, DENALI Trials, Asthma

Sanofi Provides Update on P-III PEGASUS Trial of Rilzabrutinib for the Treatment of Pemphigus

Published: Sept 9, 2021 | Tags: Sanofi, P-III, PEGASUS Trial, Rilzabrutinib, Pemphigus

AstraZeneca and Hutchmed Initiate P-III SANOVO Trial for Orpathys (savolitinib) + Tagrisso (osimertinib) as a 1L Therapy for Non-small Cell Lung Cancer in China

Published: Sept 9, 2021 | Tags: AstraZeneca, Hutchmed, P-III, SANOVO Trial, Orpathys, savolitinib, Tagrisso, Osimertinib, Non-small Cell Lung Cancer, China

Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706, a Proposed Biosimilar Avastin (bevacizumab)

Published: Sept 9, 2021 | Tags: Bio-Thera, Sandoz, BAT1706, Avastin, bevacizumab

AstraZeneca Presents Results of Fasenra in P-IIIb PONENTE Study for the Treatment of Asthma at ERS 2021

Published: Sept 8, 2021 | Tags: AstraZeneca, Fasenra, P-IIIb, PONENTE Study, Severe Asthma, ERS 2021

United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension at ERS 2021

Published: Sept 8, 2021 | Tags: United Therapeutics, Tyvaso DPI, BREEZE Clinical Study, Pulmonary Arterial Hypertension, ERS 2021

AM-Pharma Enters into an Exclusive License Agreement with Kyowa Kirin to Commercialize Ilofotase Alfa in Japan

Published: Sept 8, 2021 | Tags: AM-Pharma, Kyowa Kirin, Commercialize, Ilofotase Alfa, Japan

Google Collaborates with Mayo Clinic to Develop AI Algorithm for the Treatment of Neurological Diseases

Published: Sept 8, 2021 | Tags: Mayo Clinic, Google, AI Algorithm, Brain Stimulation Devices

Sanofi to Acquire Kadmon for ~$1.9B

Published: Sept 8, 2021 | Tags: Sanofi, Acquire, Kadmon, ~$1.9B

Genentech Signs a License Agreement with Adaptimmune to Develop and Commercialize Cancer-Targeted Allogeneic T-cell Therapies

Published: Sept 8, 2021 | Tags: Genentech, Adaptimmune, Cancer-Targeted, Allogeneic T-cell Therapies

Hetero’s Tocira (biosimilar, tocilizumab) Receives the DCGI’s EUA for the Treatment of COVID-19 in Hospitalized Adults

Published: Sept 7, 2021 | Tags: Hetero, Actemra, biosimilar, tocilizumab, DCGI, EUA, COVID-19

Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil

Published: Sept 7, 2021 | Tags: Sorrento, P-II, MSC-COV-202BR Study, COVID-19, Acute Respiratory Distress, Brazil

Impel NeuroPharma’s Trudhesa (dihydroergotamine mesylate) Nasal Spray Receives the US FDA’s Approval for the Treatment of Migraine

Published: Sept 7, 2021 | Tags: Impel NeuroPharma, Trudhesa, dihydroergotamine mesylate, Nasal Spray, US, FDA, Approval, Migraine

Advent and GIC to Acquire Sobi for ~$8B

Published: Sept 7, 2021 | Tags: Advent, GIC, Acquire, Sobi, ~$8B

NeuExcell Signs a Research Agreement with Spark to Develop a Novel Gene Therapy for Huntington’s Disease

Published: Sept 7, 2021 | Tags: NeuExcell, Spark, Novel Gene Therapy, Huntington's Disease

JW’s Relmacabtagene Autoleucel Receives the NMPA’s Approval for the Treatment of R/R Large B-Cell Lymphoma in China

Published: Sept 7, 2021 | Tags: JW, Relmacabtagene Autoleucel, NMPA, Approval, R/R Large B-Cell Lymphoma, China

Moderna’s Spikevax Receives TGA’s Provisional Approval to Treat COVID-19 in Patients Aged 12-17 Years

Published: Sept 6, 2021 | Tags: Moderna, Spikevax, TGA, Provisional Approval, COVID-19

AstraZeneca and Amgen’s Tezepelumab Demonstrates 86% Reduction in Exacerbations in Patients with Asthma and Nasal Polyps

Published: Sept 6, 2021 | Tags: AstraZeneca, Amgen, Tezepelumab, Asthma, Nasal Polyps

Bayer Reports Results of Eliapixant in P-IIb PAGANINI Study for Patients with Refractory Chronic Cough

Published: Sept 6, 2021 | Tags: Bayer, Eliapixant, P-IIb, PAGANINI Study, Refractory Chronic Cough

BioMarin Reports FDA’s Hold on P-I/II Phearless Trial of BMN 307 in Adults with PKU

Published: Sept 6, 2021 | Tags: BioMarin, FDA, P-I/II, Phearless Trial, BMN 307, PKU

Dr. Reddy’s Collaborates with Citius to Sell Rights of its Anti-Cancer Agent (E7777)

Published: Sept 6, 2021 | Tags: Dr. Reddy, Citius, Anti-Cancer Agent, E7777

Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients

Published: Sept 6, 2021 | Tags: Novartis, CIRRUS-1 Study, CFZ533, iscalimab, Kidney Transplant Patients

Related Post: PharmaShots Weekly Snapshots (August 30 – September 03, 2021)